First of Its Kind Gene Therapy Treatment Approved for Hemophilia

Share
  • November 25, 2022

A novel medication for hemophilia B has just been approved by the Food and Drug Administration. The treatment is a form of gene therapy, intended to replace a dysfunctional gene that leaves people unable to control their bleeding. It’s expected to cost $3.5 million per patient.

Read more…

Source : First of Its Kind Gene Therapy Treatment Approved for Hemophilia